Lawrence M. Gelbert

6.6k total citations · 1 hit paper
34 papers, 2.4k citations indexed

About

Lawrence M. Gelbert is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lawrence M. Gelbert has authored 34 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lawrence M. Gelbert's work include Advanced Breast Cancer Therapies (9 papers), Cancer-related Molecular Pathways (7 papers) and Gene expression and cancer classification (5 papers). Lawrence M. Gelbert is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Cancer-related Molecular Pathways (7 papers) and Gene expression and cancer classification (5 papers). Lawrence M. Gelbert collaborates with scholars based in United States, Spain and United Kingdom. Lawrence M. Gelbert's co-authors include Alfonso de Dios, Concepción Sánchez‐Martínez, Marı́a José Lallena, Rose T. Ajamie, Graham N. Wishart, Sandaruwan Geeganage, Liandong Ma, Michael Flagella, Jennifer D. Davidson and Christopher A. Slapak and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Lawrence M. Gelbert

34 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

2014 446 citations Lawrence M. Gelbert, Shufen Cai et al. Investigational New Drugs profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lawrence M. Gelbert United States	17	1.4k	962	919	667	505	34	2.4k
Simona Lamba Italy	25	1.5k 1.1×	760 0.8×	1.5k 1.6×	713 1.1×	1.0k 2.1×	39	3.3k
Florence Lerebours France	29	1.4k 1.0×	692 0.7×	915 1.0×	304 0.5×	1.2k 2.4×	97	2.6k
Maria Pik Wong Hong Kong	31	1.7k 1.2×	1.3k 1.4×	1.9k 2.0×	356 0.5×	873 1.7×	62	3.6k
Sidong Huang Canada	22	1.2k 0.8×	404 0.4×	1.9k 2.0×	518 0.8×	621 1.2×	44	2.9k
Aurora Costa Italy	21	1.7k 1.2×	338 0.4×	1.3k 1.4×	392 0.6×	754 1.5×	41	2.8k
Han‐Xiang An China	25	740 0.5×	399 0.4×	1.1k 1.2×	241 0.4×	442 0.9×	61	2.1k
Vanessa Rodrik-Outmezguine United States	16	943 0.7×	561 0.6×	2.1k 2.3×	367 0.6×	458 0.9×	32	2.8k
Diana Mandelker United States	23	867 0.6×	482 0.5×	1.3k 1.4×	388 0.6×	718 1.4×	94	2.5k
Mark R. Lackner United States	32	1.8k 1.3×	988 1.0×	2.6k 2.8×	449 0.7×	1.5k 3.0×	82	4.4k
Jonathan M. Yingling United States	26	1.3k 0.9×	502 0.5×	2.7k 2.9×	330 0.5×	385 0.8×	49	3.6k

Countries citing papers authored by Lawrence M. Gelbert

Since Specialization

Citations

This map shows the geographic impact of Lawrence M. Gelbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence M. Gelbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence M. Gelbert more than expected).

Fields of papers citing papers by Lawrence M. Gelbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence M. Gelbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence M. Gelbert. The network helps show where Lawrence M. Gelbert may publish in the future.

Co-authorship network of co-authors of Lawrence M. Gelbert

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence M. Gelbert. A scholar is included among the top collaborators of Lawrence M. Gelbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence M. Gelbert. Lawrence M. Gelbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raub, Thomas J., Graham N. Wishart, Palaniappan Kulanthaivel, et al.. (2015). Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Drug Metabolism and Disposition. 43(9). 1360–1371. 207 indexed citations

Tate, Sonya C., Shufen Cai, Rose T. Ajamie, et al.. (2014). Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts. Clinical Cancer Research. 20(14). 3763–3774. 100 indexed citations

Gelbert, Lawrence M., Shufen Cai, Xi Lin, et al.. (2014). Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investigational New Drugs. 32(5). 825–837. 446 indexed citations breakdown →

Gelbert, Lawrence M., Shufen Cai, Xi Lin, et al.. (2011). Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.. Molecular Cancer Therapeutics. 10(11_Supplement). B233–B233. 14 indexed citations

Lin, Xi, et al.. (2007). High throughput multiplexing phosphor retinoblastoma tumor suppressor protein (Rb) and cell cycle analysis using acuman technology.. Cancer Research. 67. 4372–4372. 1 indexed citations

Lu, Jianfen, Keith M. Goldstein, Peining Chen, et al.. (2005). Transcriptional Profiling of Keratinocytes Reveals a Vitamin D-Regulated Epidermal Differentiation Network. Journal of Investigative Dermatology. 124(4). 778–785. 58 indexed citations

Shou, Jianyong, Wei Tao, Chia-Ho Lin, et al.. (2005). Optimized blood cell profiling method for genomic biomarker discovery using high-density microarray. Biomarkers. 10(4). 310–320. 18 indexed citations

Onyia, Jude E., Leah M. Helvering, Lawrence M. Gelbert, et al.. (2005). Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray. Journal of Cellular Biochemistry. 95(2). 403–418. 75 indexed citations

Huang, Shuguang, et al.. (2004). At What Scale Should Microarray Data Be Analyzed?. PubMed. 4(2). 129–139. 10 indexed citations

10.

Kaiser, Sérgio, Lisa Foltz, Carolyn George, et al.. (2004). Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiology of Disease. 16(1). 220–235. 25 indexed citations

11.

Davidson, Jennifer D., Liandong Ma, Michael Flagella, et al.. (2004). An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines. Cancer Research. 64(11). 3761–3766. 249 indexed citations

12.

Huang, Shuguang, et al.. (2003). Assessing the Variability in GeneChip?? Data. PubMed. 3(4). 279–290. 12 indexed citations

13.

Wang, Jian, et al.. (2002). Aldosterone stimulates angiotensin-converting enzyme expression and activity in rat neonatal cardiac myocytes. Journal of Cardiac Failure. 8(3). 167–174. 18 indexed citations

14.

Gelbert, Lawrence M. & Richard E. Gregg. (1997). Will genetics really revolutionize the drug discovery process?. Current Opinion in Biotechnology. 8(6). 669–674. 12 indexed citations

15.

Bushar, Lauretta M., et al.. (1996). Purification of high quality DNA from shed skin. Herpetological review. 27(3). 133–134. 17 indexed citations

16.

Thliveris, Andrew, Hans Albertsen, Thérèse M.F. Tuohy, et al.. (1996). Long-Range Physical Map and Deletion Characterization of the 1100-kbNotI Restriction Fragment Harboring theAPCGene. Genomics. 34(2). 268–270. 14 indexed citations

17.

Whaley, Jean M., Joseph G. Naglich, & Lawrence M. Gelbert. (1994). Germline mutations in the VHL tumor suppresssor gene are similar to somatic VHL aberrations in sporadic renal cell carcinoma. The American Journal of Human Genetics. 55. 1 indexed citations

18.

Spirio, Lisa, Sylviane Olschwang, Joanna Groden, et al.. (1993). Alleles of the APC gene: An attenuated form of familial polyposis. Cell. 75(5). 951–957. 456 indexed citations

19.

Groden, Joanna, Lawrence M. Gelbert, Andrew Thliveris, et al.. (1993). Mutational analysis of patients with adenomatous polyposis: identical inactivating mutations in unrelated individuals.. PubMed. 52(2). 263–72. 120 indexed citations

20.

Gelbert, Lawrence M., et al.. (1990). Analysis of GPT activity in mammalian cells with a chromosomally integrated shuttle vector containing alteredgpt genes. Somatic Cell and Molecular Genetics. 16(2). 173–184. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact